Table 1.

Patient characteristics

	n	Rate	Revised SUVmax
Age
58.2 ± 12.7(21–91)	262		3.24 ± 2.64
Procedure
Breast conserving surgery	175	66.8 %	2.76 ± 2.10
Mastectomy	87	33.2 %	4.22 ± 3.28
Clinical T stage
T1	187	71.4 %	2.49 ± 1.86
T2	74	28.2 %	5.10 ± 3.32
T3	1	0.4 %	6.17
Clinical N stage
N0	203	77.5 %	3.11 ± 2.62
N1	49	18.7 %	3.59 ± 2.61
N2	7	2.7 %	4.61 ± 3.45
N3	3	1.1 %	3.72 ± 2.34
Clinical stage
I	153	58.4 %	2.35 ± 1.61
II	99	37.8 %	4.51 ± 3.27
III	10	3.8 %	4.34 ± 3.06
Pathology
Papillotubular carcinoma	42	16.0 %	2.72 ± 2.15
Solid-tubular carcinoma	46	17.6 %	4.66 ± 3.85
Scirrhous carcinoma	138	52.7 %	3.14 ± 2.38
Other ductal carcinoma	21	8.0 %	2.21 ± 1.02
Lobular carcinoma	10	3.8 %	2.09 ± 0.90
Others	5	1.9 %	4.07 ± 1.76
Nuclear grade
Grade I	67	25.6 %	2.90 ± 1.89
Grade II	99	37.8 %	2.82 ± 2.48
Grade III	96	36.6 %	3.92 ± 3.10
Lymph node metastasis
Negative	180	68.7 %	3.03 ± 2.60
Positive	82	31.3 %	3.71 ± 2.66
Vascular invasion
Negative	194	74.0 %	3.08 ± 2.55
Positive	68	26.0 %	3.72 ± 2.84

Two hundred and sixty-two luminal-type patients (luminal A and B) were evaluated in this study